Beijing Unicet’s QH104A Receives Chinese NMPA Approval for CNS Solid‑Tumor Clinical Trials
CompanyDigital

Beijing Unicet’s QH104A Receives Chinese NMPA Approval for CNS Solid‑Tumor Clinical Trials

Wolters Kluwer and the Chinese Academy of Medical Sciences Sign AI‑Driven Medical‑Information Collaboration
CompanyDeals

Wolters Kluwer and the Chinese Academy of Medical Sciences Sign AI‑Driven Medical‑Information Collaboration

Leo Pharma Secures First Greater Bay Area Prescription for Anzupgo, a Novel Topical JAK Inhibitor
Drug

Leo Pharma Secures First Greater Bay Area Prescription for Anzupgo, a Novel Topical JAK Inhibitor

Shanghai MicuRx and GenScript’s ProBio Unit Sign Strategic Deal to Accelerate Antibody‑Drug Conjugate (ADC) Development
CompanyDeals

Shanghai MicuRx and GenScript’s ProBio Unit Sign Strategic Deal to Accelerate Antibody‑Drug Conjugate (ADC) Development

NHSA Launches 100‑Day Medical‑Insurance Fraud Crackdown Campaign
Policy / Regulatory

NHSA Launches 100‑Day Medical‑Insurance Fraud Crackdown Campaign

CSPC Pharma Secures NMPA Approval for Lecanemab Biosimilar, First of Its Kind in China
CompanyDrug

CSPC Pharma Secures NMPA Approval for Lecanemab Biosimilar, First of Its Kind in China

Trump Announces 100% Tariff on Branded Drugs, Exempts U.S.‑Built Pharmaceutical Factories
CompanyDrug

Trump Announces 100% Tariff on Branded Drugs, Exempts U.S.‑Built Pharmaceutical Factories

China Unveils National Long‑Term Care Insurance Service Catalog in Pilot Phase
Policy / Regulatory

China Unveils National Long‑Term Care Insurance Service Catalog in Pilot Phase

Sichuan Biokin Secures Second Breakthrough Therapy Designation for Izalontamab Brengitecan in Advanced Urothelial Carcinoma
CompanyDrug

Sichuan Biokin Secures Second Breakthrough Therapy Designation for Izalontamab Brengitecan in Advanced Urothelial Carcinoma

Fosun Pharma’s Alovatinib Enters China’s Pediatric Anti‑Tumor SPARK Pilot
CompanyDrug

Fosun Pharma’s Alovatinib Enters China’s Pediatric Anti‑Tumor SPARK Pilot

Eli Lilly Halts Obesity Study of Experimental Drug Bimagrumab for Strategic Reasons
CompanyDrug

Eli Lilly Halts Obesity Study of Experimental Drug Bimagrumab for Strategic Reasons

Sanofi Injects an Extra USD 625 Million into Sanofi Ventures to Boost Biotech & Digital‑Health Innovation
CompanyDeals

Sanofi Injects an Extra USD 625 Million into Sanofi Ventures to Boost Biotech & Digital‑Health Innovation